Scholars Central

Conference abstractPublished 8 Jun 2015

Four days a week or less on appropriate anti HIV combinations provided long term optimal maintenance in 94 patients

Authors: Jacques Leibowitch, Dominique Mathez, Pierre de Truchis, Damien Ledu, Jean Claude melchior, Guislaine Carcelain, Jacques Izopet, Christian Perronne, John R David

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Background: Short intra-weekly cycles of anti-HIV combinations have provided intermittent yet effective therapy. The concept is now extended to 94 patients on treatment (Rx) 4 days a week (d/wk) or less over a median 2.7 discontinuous treatmentyears per patient. Patients & Combinations: On steadily suppressive combinations, 94 patients volunteered to 5 and 4 d/w treatment, or directly reduced stepwise to 4, 3, 2, 1 d/wk in respectively 94, 84, 66, 12 pts, on various triple (standard) or nonregistered quadruple antiviral combinations. Results: 4 d/wk RX aggregated 165 intermittent treatment-years recording no failure over 87 average Rx-weeks per patient; with 63/94 pts successfully passing the 144 weeks bore on any of the antiviral combinations prescribed. On highly (3d/wk) or ultra (2 d/wk) or hyper (1d/wk) intermittent Rx, HIV RNA surged >50 copies 4 weeks apart in 18 instances (6.8 viral escapes / 100 discontinuous maintenance-years), relatable to: Erratic adherence to regimen or follow-up (3 patients); base-drug at ½ the daily recommended dosage (8 pts) ; and/or overlooked archival resistant HIVs from antecedent treatment failures (6pts). Aside from such human blunders, HIV unexpectedly rebounded in 3 and 1 patients respectively on 2 and 1/d/wk Rx, = 2.2 intrinsic viral escapes per 100 ultra-hyper intermittent treatment-years. All 18 escapes were countered by 7 day-a-wk salvage combinations and 11/18 has been back to a second course of intermittent therapy 4 days a week or less. Both cell-activation markers on the surface of T- lymphocytes, and cell-bound HIV DNA levels remained stable or declined. CD4/CD8 ratios rose to ≥1 in 35% of patients, while CD4 counts went ≥500/μl in 75% - from 7% and 40% respectively on unremitting therapy. Conclusion: In our aging, long-HIV enduring, multi-treated patient cohort, ICCARRE cut into current overmedication by 60%, offering the equivalent of 3 drug-free/ 3 virus-free remission years per patient ≈3 million Euros unspent for just 94 patients, at the cost of 2.2 intrinsic viral failures per 100 ultra-hyper intermittent treatment-years. On-treatment 4 days a week would universally provide 40% cuts in dispensable medications at no risk of failure.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalVirology & Mycology
  • SubjectInfectious Diseases
  • SubjectMicrobiology
  • BylineArticles whose byline prints “Jacques Leibowitch”
  • BylineArticles whose byline prints “Dominique Mathez”
  • BylineArticles whose byline prints “Pierre de Truchis”
  • BylineArticles whose byline prints “Damien Ledu”
  • BylineArticles whose byline prints “Jean Claude melchior”
  • BylineArticles whose byline prints “Guislaine Carcelain”
  • BylineArticles whose byline prints “Jacques Izopet”
  • BylineArticles whose byline prints “Christian Perronne”